Bloomberg Businessweek ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
Jul 30, 2025
Pascal Soriot, CEO of AstraZeneca and former CEO of Genentech, shares insights on his company's remarkable performance driven by cancer drugs. He discusses the 12% revenue rise to $14.5 billion, fueled by a focus on the U.S. market. Soriot delves into the landscape of pharmaceutical manufacturing in the U.S. and the importance of strategic investments for innovation. He reflects on leadership in the industry and AstraZeneca's commitment to advancing cancer treatments and other medical breakthroughs.
AI Snips
Chapters
Transcript
Episode notes
Early U.S. Manufacturing Focus
- AstraZeneca strategically increased manufacturing in the U.S. years before recent tariff discussions.
- This foresight proved vital during COVID, supporting local production resilience.
Choose Locations With Science and Speed
- Pursue locations with strong scientific talent and institutional support.
- Prioritize responsiveness and understanding from public sector partners for rapid progress.
China's Rising Pharma Innovation
- China's pharmaceutical innovation rapidly evolved from generics to cutting-edge technologies.
- It has become a strong secondary innovation engine behind the U.S.